|drug78||ADAM Sensor Wiki||0.71|
|drug3548||Unfractionated heparin nebulized Wiki||0.71|
|drug3717||acetylsalicylic acid Wiki||0.71|
|D058186||Acute Kidney Injury NIH||0.15|
|D012141||Respiratory Tract Infections NIH||0.12|
|D003141||Communicable Diseases NIH||0.05|
There are 2 clinical trials
Hypercoagulability has been demonstrated in COVID-19, leading to respiratory distress and increased mortality. This is adaptive clinical trial to compare effectiveness and safety of four therapeutic strategies in hospital mortality in patients with COVID-19: standard prophylaxis, therapeutic dose anticoagulation, inhaled UFH associated with standard prophylaxis and ASA associated with standard prophylaxis.
Description: Number of COVID-19 positive patients who are alive within 30 days of symptoms onsetMeasure: Hospital discharge - alive / death Time: 30 days
Description: Comparison of length of mechanical ventilation free days between each treatment armMeasure: Length of mechanical ventilation free days Time: 30 days
Description: Comparison of length of renal replacement therapy free days between each treatment armMeasure: Length of renal replacement therapy free days Time: 30 days
Description: Comparison of number of thrombosis events between each treatment arm.Measure: Number of documented venous thromboembolism or arterial thrombosis Time: 3 months
Since the emergence of the new strain of betacoronavirus (SARS-CoV-2) and its important clinical repercussions, it has been described that patients with its associated pneumonia (COVID-19) have high rates of thrombotic events, including reduction in the dialyzers patency when undergoing renal replacement therapy. Several strategies for preventing the early loss of dialysers are described, and regional anticoagulation based on citrate is the preferred modality for preventing this complication. On the other hand, in patients with SARS-CoV-2 there are already descriptions of endothelial inflammation and activation of the coagulation cascade, including studies demonstrating the benefit of heparinization of these patients. Thus, this study aims to compare two different anticoagulation strategies in patients infected with COVID-19 with continued venovenous hemodialysis (CVVHD). From the indication of CVVHD, patients will be screened according to eligibility criteria and, if they fit these parameters, they will be randomized into two groups: Group A - Standard regional anticoagulation based on Citrate associated with infusion of low doses of unfractionated heparin 10ui/kg/hour and Group B - Standard regional anticoagulation based on Citrate only. Patients will be randomized in blocks and followed for 72 hours. The primary endpoint is dialyzer patency at the end of 72 hours of clinical follow-up. Secondary objectives will be mortality, bleeding rate, drop in hematimetric indices, urea sieving, filter time in hours, down time of therapy, system and dialyser pressures (PBE and PTM). All patients will undergo a standard procedure with a prescribed dose of 30mL/Kg/H, blood flow of 150mL/minute and polysulfone dialyzer.
Description: The percentage of clotted dialyzers within 72 hours in each of the studied groups.Measure: Clotted dialyzers Time: Day 3 of dialysis
Description: Number of hours until a dialyzer clots in the first 72 hours of dialysisMeasure: Time-free of clotting Time: Day 3 of dialysis
Description: The amount of dialyzers used in the first 72 hours of hemodialysisMeasure: Number of dialyzers used Time: Day 3 of dialysis
Description: Variation in dialysis system and vascular access pressures in the first 72 h of dialysisMeasure: Pressure variation Time: Day 3 of dialysis
Description: Variation in urea sieving between the first, second and third days of dialysisMeasure: Urea sieving Time: Day 3 of dialysis
Description: Time of dialysis stop due to clotting in the first 72 hoursMeasure: Downtime of dialysis Time: Day 3 of dialysis
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports